NASDAQ:SNTI • US81726A2096
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SENTI BIOSCIENCES INC (SNTI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-21 | Leerink Partners | Initiate | Outperform |
| 2025-10-14 | HC Wainwright & Co. | Initiate | Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-06 | Laidlaw & Co. | Initiate | Buy |
| 2025-05-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-08-15 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-03-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2023-03-23 | Chardan Capital | Maintains | Buy |
| 2023-01-30 | Chardan Capital | Maintains | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-12-16 | JP Morgan | Initiate | Neutral |
| 2022-10-07 | Morgan Stanley | Initiate | Equal-Weight |
| 2022-09-29 | B of A Securities | Initiate | Buy |
| 2022-09-23 | Chardan Capital | Initiate | Buy |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.761M 387.81% | 4.286M 55.23% | 2.561M -40.25% | 2.856M -100.00% | 680.003K | 1.7M 150.00% | -100.00% | 6.97M | 45.101M 547.07% | 155.99M 245.87% | 322.59M 106.80% | 343.33M 6.43% | 379.24M 10.46% | |
| EBITDA YoY % growth | -39.677M -64.43% | -60.686M -52.95% | -63.204M -4.15% | -64.26M 9.99% | -61.2M -7.58% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -40.446M -63.79% | -62.084M -53.50% | -66.765M -7.54% | -64.26M 9.05% | -67.304M -10.83% | -83.015M -23.34% | -99.763M -20.18% | -115.274M -15.55% | -106.902M 7.26% | -24.01M 77.54% | 112.9M 570.22% | N/A | N/A | |
| Operating Margin | -1,464.90% | -1,448.53% | -2,606.99% | -2,250.00% | -9,897.55% | -4,883.24% | N/A | -1,653.86% | -237.03% | -15.39% | 35.00% | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A 91.40% | -14.83 -848.26% | -2.70 81.81% | -1.44 46.79% | -1.64 -14.03% | -1.91 -16.51% | -1.70 10.96% | -0.23 86.49% | 2.21 1,064.44% | N/A | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.42 37.20% | -0.43 | -0.32 42.63% | -0.41 40.13% | -0.34 18.79% |
| Revenue Q2Q % growth | 680.003K | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -16.187M -0.12% | -18.768M -14.46% | -19.584M -16.59% | -20.4M -20.37% | -21.318M -31.70% |
All data in USD
10 analysts have analysed SNTI and the average price target is 11.73 USD. This implies a price increase of 1244.88% is expected in the next year compared to the current price of 0.8722.
The consensus EPS estimate for the next earnings of SENTI BIOSCIENCES INC (SNTI) is -0.42 USD and the consensus revenue estimate is 680.00K USD.
The consensus rating for SENTI BIOSCIENCES INC (SNTI) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.